Transcription Regulation by Class III Histone Deacetylases (HDACs)—Sirtuins by Dai, Yan & Faller, Douglas V.
Translational Oncogenomics 2008:3 53–65 53
REVIEW
Correspondence: Yan Dai, Ph.D., 715 Albany Street, Boston, MA 02118. Tel: 617-638-5650; 
Email: yandai@bu.edu
Copyright in this article, its metadata, and any supplementary data is held by its author or authors. It is published under the 
Creative Commons Attribution By licence. For further information go to: http://creativecommons.org/licenses/by/3.0/.
Transcription Regulation by Class III Histone Deacetylases 
(HDACs)—Sirtuins
Yan Dai and Douglas V. Faller
Cancer Research Center and Department of Medicine, Boston University School of Medicine, 
Boston, Massachusetts 02118, U.S.A.
Abstract: Sirtuins are NAD
+-dependent histone deacetylases (Class III HDACs). Recently, Sirtuins have been shown to 
play important roles, both direct and indirect, in transcriptional regulation. This transcriptional control, through incorpora-
tion of Sirtuins into transcription complexes and deacetylation of histones locally at gene promoters, or direct interaction 
with speciﬁ  c transcription factors, is central to the participation of Sirtuins in multiple diverse processes, including aging, 
apoptosis, hormone responses, stress tolerance, differentiation, metabolism and development. Here we review the contribu-
tion of the Sirtuin family, at multiple molecular levels, to transcriptional regulation.
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Introduction
The modiﬁ  cation of histones and transcription factors by acetylation and deacetylation play a central role 
in the control of transcription. Acetylation of histones is postulated to increase DNA accessibility through 
the neutralization of the positive charges of lysine residues. This modiﬁ  cation correlates generally with 
transcriptional activation. Histone acetylation is catalyzed by histone acetyl transferases (HATs), whereas 
the reverse reaction is performed by histone deacetylases (HDACs). HATs and HDACs participate in the 
genome-wide turnover of acetyl groups on histones and, in addition, on many transcription factors. Through 
their physical interactions with DNA sequence-speciﬁ  c transcription factors, they are also targeted to 
speciﬁ  c promoters, where they locally modify histones or transcription factors or transcriptional co-
activators/co-repressors, and thus can regulate gene transcription at multiple molecular levels.
HATs and HDACs are classiﬁ  ed into numerous families that are often conserved from yeast to 
humans. Histone deacetylases (HDACs) are divided into three classes. Class I members (HDACs 1, 2, 
3, 8, 11) are transcriptional co-repressors homologous to yeast RPD3 [1]. HDAC class II members 
(HDACs 4, 5, 6, 7, 9, 10) have domains similar to yeast HDA1 [2]. Class III histone deacetylases (Sir-
tuins) are structurally distinct from class I and II HDACs, and are homologues of the yeast silent infor-
mation regulator 2 (Sir2) [3, 4]. Class III HDACs are NAD
+-dependent histone deacetylases, wherein 
their deacetylase activity is controlled by the cellular [NAD
+]/[NADH] ratio. The mammalian homo-
logues of the Sirtuin family proteins consist of seven members, SIRT1—SIRT7 [5]. SIRT1 (also known 
as Sir2α) is the closest homologue of yeast Sir2 and has been the most extensively studied.
All seven Sirtuins are ubiquitously expressed in humans, and histones H1, H3 and H4 appear to be 
the histone protein targets of the class III histone deacetylases. A growing number of non-histone sub-
strates have also been shown to be deacetylated by Sirtuin family members, greatly expanding the 
potential biological roles of Sirtuins. These non-histone Sirtuin substrates range in class from structural 
to adhesion to signaling molecules, and the activity of these protein targets of Sirtuins, or their sub-
cellular localization, or their association with other proteins, can be modiﬁ  ed by their acetylation state. 
Non-histone Sirtuin targets related to transcriptional control include many DNA-binding transcription 
factors, such as the forkhead box type O transcription factors (FOXO) [6–10], p53 [11–13], nuclear 
factor-κB (NFκB) [14] and the peroxisome proliferator activated receptor-γ (PPARγ) [15], the androgen 
receptor [16, 17] and their co-regulatory molecules. In this review, we will review the basic underlying 
principles of Sirtuin family member actions on transcriptional regulation and the major advances that 
have occurred in this ﬁ  eld in recent years.54
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Regulation of Transcription Factor 
Function by Sirtuins
Numerous mammalian transcription factors and their 
co-regulatory proteins have been identiﬁ  ed as targets 
of the Sirtuins gene products (Table 1). The deacet-
ylation of transcription factors by Sirtuins can 
regulate their activities in a number of ways, includ-
ing: (i) altering their sub-cellular location; (ii) chang-
ing their expression level; (iii) altering their binding 
to DNA; and, (iv) changing their interactions with 
regulatory proteins (Fig. 1). (Regulation of 
transcription factors by Sirtuins often involves more 
than one of these mechanisms simultaneously).
Alteration of the sub-cellular 
localization of transcription factors 
by Sirtuins
Nucleocytoplasmic shuttling of transcription fac-
tors is an important mechanism in transcription 
regulation. The acetylation or deacetylation of a 
transcription factor can directly regulate the 
accessibility of nuclear localization signals ( NLSs) 
and nuclear export signals (NESs) to nuclear 
import and export proteins. SIRT1 is implicated in 
regulating the sub-cellular localization of several 
transcription factors, including members of the 
FOXO transcription factor family. However, the 
precise molecular mechanism regulating the shut-
tling of FOXO by Sirtuins is not yet clear.
Forkhead box O (FOXO) transcription factors, 
including FOXO1, FOXO3a, FOXO4 and FOXO6, 
the mammalian orthologs of Caenorhabditis ele-
gans DAF-16, are emerging as a central family of 
proteins that modulate the expression of genes 
involved in apoptosis, cell cycle progression, DNA 
damage repair, responses to oxidative stress, cell 
differentiation, glucose metabolism and other cel-
lular functions [18, 19]. FOXO proteins are regu-
lated by post-translational modiﬁ  cations, including 
phosphorylation and acetylation [20, 21]. In grow-
ing cells, FOXO proteins are predominantly cyto-
plasmic, and nuclear import of FOXO proteins is 
triggered by oxidative stress or DNA damage. 
Table 1. Transcription factors and their coregulators are listed that have been shown to be deactylated 
by Sirtuins.
Substrate Sirtuins Functions and references
FOXO1 SIRT1 Inhibit apoptosis (6); Increase glucose release (7)
SIRT2 regulator of adipocyte differentiation (22)
FOXO3 SIRT1 Induce cell cycle arrest and inhibit apoptosis (8); Inhibit Apoptosis (9)
SIRT2 Promote cell death, induce cell cycle arrest (41)
FOXO4 SIRT1 Promote cellular survival and increase life span (10)
p53 SIRT1 Inhibit apoptosis (11, 12); antagonize PML/p53-induced cellular senescence (13)
p73 SIRT1 Inhibit apoptosis (38)
NFκB SIRT1 Increase TNFalpha induced apoptosis (14)
PPARγ SIRT1 Promotes fat mobilization (15)
AR SIRT1 Suppression of AR mediated transcription (16, 17)
Smad7 SIRT1 Attenuates Smad7-induced mesangial cell apoptosis (32)
E2F SIRT1 Inhibition of apoptosis (39)
Rb SIRT1 Suppressor of Rb (40)
P300 SIRT1 Suppressor of p300 (44)
PGC-1 SIRT1 Activates gluconeogenesis and represses glycolysis (45,46), protected diet-induced-
obesity and insulin resistance [47]; promote the activation of mitochondrial fatty acid 
oxidation genes [48] and regulate cellular oxygen consumption [49]
SIRT3 Reactive oxygen species production and increase cellular respiration (50)
CTP1/CTP2 SIRT1 Stimulates CTIP-dependent transcriptional repression (51, 52)
bHLH and 
HES
SIRT1 Enhance the transcription suppression in metazoan development (53)
HIC1 SIRT1 Positively control HIC1 transcriptional repression activity (54)
Tat SIRT1 Transcriptional coactivator during Tat transactivation (56)55
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SIRT1 deacetylates FOXO1 at Lys-242, -245, and 
-262, overrides the phosphorylation-dependent 
nuclear exclusion of FOXO1 caused by growth 
factors, and induces the nuclear translocation of 
FOXO1 [7]. FOXO1 is readily diffusible within 
the nucleus under normal conditions but becomes 
restricted within a nuclear subdomain following 
treatment with the prototypical Sirtuin agonist 
resveratrol, or after exposure to oxidative stress, 
leading to the expression of FOXO1 target genes, 
and ultimately inducing gluconeogenesis and glu-
cose release from hepatocytes [7]. (FOXO protein 
transcriptional activity and stability are also 
directly altered through deacetylation of FOXO by 
SIRT1, and these additional levels of FOXO regu-
lation by SIRT1 will be discussed below).
SIRT2, another member of the class III HDAC 
family, regulates FOXO1 translocation in 3T3-L1 
adipocytes [22]. SIRT2, a cytoplasmic Sirtuin, is 
the most abundant Sirtuin in adipocytes. SIRT2 
directly associates with, and deacetylates, FOXO1, 
leading to changes in FOXO1 phosphorylation, 
enhanced nuclear localization, and inhibition of 
adipogenesis. Thus, SIRT2 acts as an important 
regulator of adipocyte differentiation through 
modulation of FOXO1 acetylation/phosphoryla-
tion and activity [22].
FOXO3 localization is regulated by SIRT1; 
translocation of FOXO3 from the cytoplasm to the 
nucleus is induced by SIRT1 in response to oxida-
tive stress [8]. In the presence of growth factors and 
the absence of stress, FOXO3 is cytoplasmic. In 
cells subjected to various stresses, including oxida-
tive stress, FOXO3 relocates to the nucleus. SIRT1 
forms a complex with deacetylated FOXO3 in the 
nucleus, inducing cell-cycle arrest and resistance 
to oxidative stress, but simultaneously inhibiting 
the ability of FOXO3 to induce apoptosis [8].
The examples described above demonstrate that 
deacetylation of FOXO transcription factors by 
SIRT1 promotes their nuclear translocation. How-
ever, FOXO regulation by SIRT1 appears to occur 
at multiple levels. SIRT1 has been shown to 
associate with, and deacetylate, FOXO proteins in 
Figure 1. Sirtuins regulates multiple aspects of transcription. SIRT1 can deacetylate transcription factors (TF) and regulate their functions 
by altering their sub-cellular location, changing their expression level, altering their binding to DNA and changing their interactions with 
regulatory proteins. SIRT1 can also directly deacetylate co-repressor or co-activator, histone and interact with chromatin remodeling proteins 
to regulate transcription.
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the nucleus. A FOXO3 mutant with three Akt 
phosphorylation sites mutated to alanine has been 
shown to reside permanently in the nucleus, but 
does not interact with SIRT1 in the absence of 
stress signals [8], suggesting that nuclear localiza-
tion of FOXO3 alone is not sufﬁ  cient to promote 
an interaction with nuclear SIRT1, and that some 
form of phosphorylation or other modiﬁ  cation of 
FOXO3 might be required for the interaction 
between FOXO3 and SIRT1. Although SIRT1 is 
reported to be predominantly nuclear in localiza-
tion, SIRT1 has also been found recently to also 
be resident in the cytoplasm, and can shuttle 
between the nucleus and cytoplasm [23–28]. 
Whether or not cytoplasmic SIRT1 plays a role in 
FOXO3 localization requires further study.
The control of transcription factor 
stability by Sirtuin-mediated 
deacetylation
The control of the transcription factor protein lev-
els is another important mechanism in transcription 
regulation. The acetylation status of the lysine 
residues on a protein can exert important direct 
regulatory control of that protein’s stability [29]. 
Acetylation of certain transcription factors on 
lysine residues protects them from degradation, 
thereby promoting their transcriptional activity [30, 
31]. Conversely, the deacetylation of these tran-
scription factors by SIRT1 adversely affects their 
stability by regulating the covalent attachment of 
ubiquitin to lysine residues. Lysine acetylation is 
one mechanism controlling the stability of the 
Smad7 transcription factor; SIRT1-dependent 
deacetylation of Smad7 promotes its ubiquitination 
and degradation [32]. Other examples in which 
SIRT1 has been shown to regulate transcription 
factor protein stability include FOXO [33], andro-
gen receptor [16], PGC-1α [34] and p53 [35].
The Smad family of signal transduction mole-
cules are components of a critical intracellular 
pathway that transmits TGF-β signals from the cell 
surface into the nucleus. Once in the nucleus, 
Smads target a variety of DNA-binding proteins 
to regulate transcriptional responses. SIRT1 
directly interacts with the N-terminus of Smad7 
and thereby regulates transforming growth factor 
β (TGFβ)-induced apoptosis in renal glomerular 
mesangial cells [32]. SIRT1 reverses histone 
acetyl-transferase (HAT) p300-mediated acetyla-
tion of two lysine residues (Lys-64 and -70) on 
Smad7. In mesangial cells, the expression level of 
Smad7 is reciprocally reduced by SIRT1 over-
expression and increased by SIRT1 knockdown. 
SIRT1-mediated deacetylation of Smad7 enhances 
Smad ubiquitination regulatory factor 1 (Smurf1)-
mediated ubiquitin proteasome degradation, which 
contributes to the low levels of Smad7 expression 
in SIRT1-overexpressing mesangial cells. SIRT1 
over-expression attenuates Smad7-induced mesan-
gial cell apoptosis, whereas SIRT1 knockdown 
enhances this apoptotic response [32].
While FOXO transcription factors are regulated 
by Sirtuins predominantly via reversible changes 
in their sub-cellular localization, the stability of 
FOXO proteins represents an additional and irre-
versible level of regulation for this family of tran-
scription factors. Degradation of FOXO 
transcription factors is mediated by the ubiquitin-
proteasome pathway. In addition to phosphoryla-
tion modiﬁ  cations, acetylation also plays a role in 
the control of ubiquitin-mediated FOXO protein 
degradation. Acetylation of FOXO1 prevents its 
ubiquitin-dependent degradation [33]. Our unpub-
lished data demonstrates that SIRT1 down-
regulation in prostate cancer cell lines increases 
the levels of FOXO3a protein, suggesting a role 
for deacetylation by SIRT1 in ubiquitin-mediated 
FOXO3a protein degradation.
The androgen receptor (AR) is a ligand-regulated 
modular nuclear receptor governing prostate cancer 
cellular proliferation, differentiation, and apoptosis 
in response to androgens. SIRT1 binds to, and 
deacetylates, the androgen receptor at a conserved 
lysine motif, down-regulating its levels in the cell, 
and repressing androgen-induced AR transcrip-
tional activity [16].
The protein level of the p53 tumor suppressor 
is regulated by SIRT1. p53 is stabilized by acetyla-
tion of Lys-382, and this residue is a known target 
of SIRT1-mediated deacetylation [35]. As p53 
plays a central role in critical cellular processes 
and fates, including DNA repair, apoptosis, cell 
cycle arrest, senescence and transformation, mul-
tiple pathways regulating cell fate may operate 
through Sirtuins on p53. For example, Nampt, a 
longevity protein, extends the lifespan of human 
smooth muscle cells by activating SIRT1 and 
restraining the accumulation of p53 [35]. The 
transcriptional activity of p53 is also regulated by 
Sirtuins at the level of DNA-binding, and the tran-
scription of the SIRT1 gene is reciprocally regulated 
by p53, as discussed below.57
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One mechanism of transcriptional regulation 
involves the replacement of core histones with more 
specialized variants, and Sirtuins has a role in 
regulating the stability of variant histones [24]. 
H2A.z is one such histone variant and serves as a 
transcriptional regulator essential for development 
of mammals [36]. Histone variant H2A.z is up-
regulated during cardiac hypertrophy and is 
required for this pathological response, and H2A.z 
stability and the extent of myocyte cell growth and 
apoptosis are moderated by Sir2α (the mouse 
homologue of yeast Sir2) [24]. Over-expression of 
Sir2α specifically induces down-regulation of 
H2A.z via a NAD
+-dependent activity. This effect 
is reversed by the proteasome inhibitor epoxomicin, 
suggesting a Sir2α-mediated ubiquitin/proteasome-
dependent mechanism for degradation of H2A.z. 
Sir2α directly deacetylates H2A.z, and Lys-115 and 
a conserved, ubiquitinatable Lys-121 are critical 
for Sir2α-mediated degradation. Sir2α is therefore 
involved in the deacetylation of H2A.z, leading to 
the ubiquitination of Lys-115 and Lys-121 and the 
consequent degradation of H2A.z via a ubiquitin/
proteasome-dependent pathway [24].
Regulation of transcription factor 
binding to DNA by Sirtuins
The binding of transcription factors to gene pro-
moters can be regulated by Sirtuins-mediated 
acetylation. As one example, the acetylation of 
lysine residues in the C-terminal regulatory domain 
of p53 enhances the sequence-speciﬁ  c binding of 
p53. SIRT1 deacetylates p53 at Lys-382 in the 
C-terminal domain and represses its transcriptional 
activity [11, 37]. As a consequence, SIRT1 
represses p53-dependent apoptosis in response to 
DNA damage and oxidative stress, and promotes 
cell survival under cellular stress induced by agents 
such as etoposide or irradiation. Interestingly, as 
SIRT1 transcription is directly repressed by p53, 
SIRT1-induced repression of p53 function is likely 
to result in feed-forward induction of SIRT1 pro-
tein levels. p73 is also a target of SIRT1, and direct 
deacetylation of p73 by SIRT1 changes the DNA-
binding ability of this factor and reduces its tran-
scriptional activity [38].
Binding of the central transcription factor and 
tumor suppressor E2F1 to its cognate gene pro-
moter elements and their subsequent transcrip-
tional activation, are stimulated by acetylation 
through PCAF. SIRT1 deacetylates E2F and 
suppresses its transcriptional activity, most likely 
through suppression of its DNA-binding activity 
[39]. As the SIRT1 gene is a transcriptional target 
of E2F1, this may provide some auto-regulation 
of SIRT1 levels in the cell, with SIRT1 repressing 
its own transcription through E2F (while stimulat-
ing its own transcription through inhibition of p53 
activity).
SIRT1 physically interacts with the RelA/p65 
subunit of NFκB and inhibits NFκB-induced tran-
scription, by deacetylating RelA/p65 at Lys-310. 
Increases in SIRT1 activity delays TNFα-induced 
recruitment of NFκB complexes containing RelA/
p65 and p50 proteins to NFκB-regulated gene 
promoters [14].
SIRT1 is a binding partner for the retinoblas-
toma tumor suppressor protein (Rb) and its family 
members, p107 and p130, and SIRT1 is an in vitro 
and in vivo deacetylase for the Rb protein [40]. 
Active Rb is acetylated in multiple residues and 
inactivation of Rb involves deacetylation of lysine 
residues within Rb. p300 catalyzes the acetylation 
and activation of Rb, whereas SIRT1 is a potent 
deacetylase for Rb. The deacetylated lysine resi-
dues within Rb form a domain similar to the 
SIRT1-targeted domain of the p53 tumor suppres-
sor protein. The deacetylation of Rb by SIRT1 
results in the inhibition of Rb tumor suppressor 
activity.
Sirtuins have been shown to directly deacetylate 
members of the FOXO transcription factor family 
and alter their transcriptional activity. Since many 
FOXO acetylation sites are located within the 
DNA-binding domain of the molecule, it is pos-
sible that acetylation of FOXO interferes with 
FOXO binding to DNA and thereby inhibits 
FOXO-dependent transcription. For example, 
SIRT1 has been shown to preferentially deacety-
late FOXO1 at K242, K245, and K262, thereby 
altering its DNA-binding ability, and activating 
the transcriptional function of FOXO1 in a deacet-
ylase-activity dependent manner [41, 42]. As 
another example, SIRT2 binds to FOXO3 and 
reduces its acetylation levels. SIRT2 thereby 
increases FOXO3 DNA-binding activity and 
elevates the expression of FOXO target genes. 
As a consequence, SIRT2 activation, through 
FOXO3, decreases cellular levels of reactive 
oxygen species and induces cell cycle arrest. 
Furthermore, as Bim is a pro-apoptotic factor, 
SIRT2 promotes cell death when cells are sub-
jected to severe stress [43].58
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Sirtuins can also regulate transcription by 
affecting the activity of the basal transcription 
machinery. Acetylation of TAFI68, a subunit of the 
RNA polymerase I complex, enhances the binding 
of TAFI68 to rRNA gene promoters and induces 
rRNA gene transcription in mammals. Sir2a 
deacetylates TAFI68 and decreases the binding of 
TAFI68 to rDNA promoters and represses rDNA 
gene transcription [44]. Thus, TAFI68 represents 
a new class of Sirtuin substrates whose site-speciﬁ  c 
DNA-binding activity is decreased by the action 
of these class III HDACs.
Regulation of the interactions 
of transcription factors with their 
co-regulators by Sirtuins
In addition to regulating transcription factors at the 
levels of the sub-cellular localization, protein sta-
bility and DNA-binding ability, SIRT1 can also 
modulate intrinsic transcription factor activity 
through alteration of the afﬁ  nity of the factors for 
their co-activators, co-repressors or the general 
transcription machinery. Sirtuins could modulate 
such interactions directly, by deacetylating residues 
on the transcription factors or the co-regulatory 
molecules which form parts of interacting surfaces, 
thereby blocking or facilitating interactions, or 
indirectly, with deacetylation inducing a confor-
mational change in another part of the molecule 
which unmasks or masks binding surfaces.
SIRT1-mediated deacetylation enhances 
FOXO1 and CCAAT/enhancer-binding protein 
alpha (C/EBPα) interactions, thereby promoting 
the transcription of adiponectin, an adipose tissue-
derived hormone which plays an important role in 
maintaining energy homeostasis [45]. C/EBPα acts 
as a co-activator of FOXO1, which accesses the 
adiponectin promoter through two FOXO1-binding 
sites. FOXO1 interacts with C/EBPα to form a 
transcription complex and up-regulates adiponec-
tin gene transcription. In addition to enhancing 
FOXO1—C/EBPα interactions [45], SIRT1 also 
acts to increase adiponectin transcription in adipo-
cytes by activating FOXO1 directly through its 
deacetylation (see above).
Transcription factor PPARγ is a key regulator 
of adipogenesis and fat storage, controlling the 
expression of many adipocyte-specific genes. 
SIRT1 actively represses PPARγ activity via 
enhancing PPARγ docking with two of its co-
repressors, NcoR (nuclear receptor co-repressor) 
and SMRT (silencing mediator of retinoid and 
thyroid hormone receptor). Hence, SIRT1 acts as 
a co-repressor of PPARγ-mediated transcription, 
attenuating adipogenesis [15].
The androgen receptor (AR) is a ligand-regulated 
modular nuclear receptor governing prostate cancer 
cellular proliferation, differentiation, and apoptosis 
in response to androgens. We have demonstrated 
ligand-dependent recruitment of SIRT1 as a 
co-repressor into a transcription complex [17], the 
ﬁ  rst example of conditional recruitment of SIRT1 
into a transcription complex. SIRT1 recruitment is 
required for androgen antagonist-mediated tran-
scriptional repression and growth suppression of 
AR-responsive genes. Androgen antagonist-bound 
androgen receptor (AR) recruits SIRT1 and nuclear 
receptor co-repressor (NCoR) to AR-responsive 
promoters and deacetylates histone H3 locally at 
these promoters.
Regulation of transcription factor 
co-regulator protein function by Sirtuins
In addition to direct regulation of transcription 
factors themselves, increasing evidence suggests 
that co-regulatory factors, including p300, PGC1 
and CTIP1/CTIP2, are also directly targeted by 
Sirtuins.
The p300 protein serves as a rate-limiting tran-
scriptional co-integrator of diverse transcription 
factors, either activating or repressing transcription 
through its modular subdomains. SIRT1 physically 
interacts with, and represses transactivation by, 
p300. Two residues within the CRD1 domain of 
p300 (Lys-1020 and Lys-1024) are required for 
repression by SIRT1 and serve as substrates for 
SIRT1 deacetylation. Because p300 is a gating 
transcriptional cofactor, deacetylation and repres-
sion of p300 by SIRT1 may serve as an important 
integration point during metabolic processes and 
cellular differentiation [46].
The transcriptional co-activator PGC-1α plays 
an important role in hepatic and systemic glucose 
and lipid metabolism and respiration, as well as 
caloric restriction. In mammals, maintenance of 
energy and nutrient homeostasis during food depri-
vation is accomplished through an increase in 
mitochondrial fatty acid oxidation in peripheral 
tissues. PGC-1α is an important component driving 
this cellular oxidative process, and SIRT1 interacts 
with PGC-1α and deacetylates it at multiple lysine 
residues, to activate PGC-1α-mediated transcription. 59
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Fasting induces PGC-1α deacetylation in skeletal 
muscle and SIRT1 deacetylation of PGC-1α is 
required for activation of mitochondrial fatty acid 
oxidation genes. SIRT1 therefore serves as a func-
tional regulator of PGC-1α regulating a metabolic 
gene transcription program of mitochondrial fatty 
acid oxidation. SIRT1, via deacetylation of 
PGC-1α, activates gluconeogenesis and represses 
glycolysis in the liver [47, 48]; protects mice 
against diet-induced obesity and insulin resistance 
[49]; promotes the activation of mitochondrial fatty 
acid oxidation genes [50] and regulates cellular 
oxygen consumption [51]. Many of the metabolic 
changes induced by SIRT1 knockdown or SIRT1 
over-expression are dependent upon PGC-1α [48]. 
Treatment with resveratrol (a SIRT1 activator) 
protects mice against diet-induced obesity and 
insulin resistance [49] (although SIRT1 is not the 
only target of resveratrol, and has not been shown 
to be the critical functional target of the drug in 
these studies). This regulation of energy and 
metabolic homeostasis by SIRT1 has implications 
for understanding the consequences of selective 
nutrient adaptation and how it might impact lifes-
pan or metabolic diseases such as obesity and 
diabetes [50].
SIRT3 is localized to the mitochondrial inner 
membrane. Caloric restriction activates SIRT3 
expression in both white and brown adipose tissue. 
SIRT3 interacts with and deacetylates PGC-1α to 
activate mitochondria functions, and plays an 
important role in adaptive thermogenesis in brown 
adipose tissue [52]. Enforced expression of SIRT3 
in HIB1B brown adipocytes enhances the expres-
sion of PGC-1α, the uncoupling protein UCP1, 
and a series of mitochondria-related genes. In addi-
tion, SIRT3 stimulates CREB phosphorylation, 
which reportedly activates the PGC-1α promoter 
directly. Functionally, sustained expression of 
SIRT3 decreases membrane potential and reactive 
oxygen species production, while increasing cel-
lular respiration [52].
Chicken ovalbumin upstream promoter tran-
scription factor II (COUP-TF II)-interacting pro-
teins 1 and 2 (CTIP1 and CTIP2) enhance 
transcriptional repression mediated by COUP-TF 
II and have been implicated in hematopoietic cell 
development and malignancies. CTIP1 and CTIP2 
are also sequence-speciﬁ  c DNA-binding proteins 
that repress transcription through direct, COUP-
TF-independent binding to a GC-rich response 
element. SIRT1 interacts directly with CTIP1/
CTIP2 and is recruited to specific promoter 
elements in a CTIP1/CTIP2-dependent manner. 
SIRT1 enhances the deacetylation of template-
associated histones H3/H4 in CTIP-transfected 
cells (see below), and stimulates CTIP-dependent 
transcriptional repression [53, 54].
Sirtuins as regulatory components 
of transcription factor complexes
Recent reports now clearly demonstrate that SIRT1 
can form complexes with certain transcription fac-
tors bound to promoter elements, and regulate their 
transcriptional activity. The biochemical mecha-
nisms underlying of transcription regulation by 
SIRT1 in these complexes are not clearly deﬁ  ned 
in every case, and may include local histone 
deacetylation at the promoter, direct deacetylation 
of other members of the complex, or a change the 
ratio of co-activators/co-repressors within the 
transcription complex (and more than one such 
SIRT1-mediated mechanism may be simultane-
ously operative within the same complex).
The basic helix—loop—helix (bHLH) super-
family of transcription factors comprises a large 
number of proteins which play important roles as 
activators or repressors in diverse aspects of devel-
opment. SIRT1 physically associates with the 
human bHLH repressor proteins hHES1 and 
hHEY2, both in vitro and in vivo, and enhances the 
transcriptional repression mediated by these bHLH 
repressors [55].
Tumor suppressor HIC1 (hypermethylated in 
cancer 1) encodes a zinc-ﬁ  nger transcription factor 
that is essential for mammalian development, 
which is epigenetically silenced in many human 
tumors and is involved in a complex pathway 
regulating p53 tumor suppression activity. Two 
deacetylases, SIRT1 and HDAC4, interact and 
form a dual-deacetylase complex with the tran-
scriptional repressor HIC1, enhancing the tran-
scriptional suppressor effect of HIC1 [56]. The 
activity of HIC1 as a transcriptional repressor is 
inhibited by its acetylation by the HATs CBP/p300. 
SIRT1 deacetylates HIC1 at the same lysine resi-
dues, and promotes its sumoylation, resulting in 
restoration of the repressor activity of HIC1 [56]. 
In a autoregulatory loop analogous to SIRT1 sup-
pression of E2F transcriptional activity and p53 
transcriptional repressor activity (discussed above), 
because HIC1 is a transcriptional repressor of the 
SIRT1 gene, one result of SIRT1 interactions with 60
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HIC1-containing transcriptional repressor 
complexes is down-regulation of SIRT1 gene 
expression [57].
SIRT1 acts predominantly as a co-repressor of 
gene expression through protein deacetylation. 
However, there is evidence that SIRT1 can also 
serve as a co-activator, positively-regulating gene 
expression. As one example, the human immuno-
deﬁ  ciency virus (HIV) Tat protein is acetylated by 
the transcriptional co-activator p300. SIRT1 
recycles Tat to its unacetylated form and acts as a 
transcriptional co-activator during Tat transactiva-
tion [58]. Tat and SIRT1 association in a DNA-
bound transcription factor complex synergistically 
activates the HIV promoter.
Regulation of Transcription 
at the Nucleosomal Level by Sirtuins
In addition to its pleiotropic effects on speciﬁ  c 
non-histone target proteins, SIRT1 also regulates 
transcription by deacetylating histones and inter-
acting with chromatin-remodeling complexes.
Deacetylation of histones at gene 
promoters by Sirtuins
A diverse array of post-translational modiﬁ  cations 
within the tail domains of histones have been 
shown to regulate chromatin structure and hence 
regulate gene transcription. SIRT1 preferentially 
deacetylates H3-K9, H3-K14 and H4-K16 in vitro 
and in vivo [59].
Certain transcription factors, including CTIP1, 
CTIP2, and AR, can recruit SIRT1 to target gene 
promoters, with resulting local deacetylation of 
either histones H3 or H4, thereby repressing gene 
transcription.
As discussed above, CTIP1 (BCL11A) and 
CTIP2 (BCL11B) are transcriptional repressors 
which bind directly to a GC-rich motif and are also 
indirectly recruited to promoter elements via inter-
action with the orphan nuclear receptor, chicken 
ovalbumin upstream promoter transcription factor 
II (COUP-TF II). SIRT1 interacts directly with 
CTIP1 and CTIP2 and is recruited to the promoter 
template in a CTIP1/CTIP2-dependent manner, 
leading to transcriptional repression. Chroma-
tin immunoprecipitation assays revealed that 
expression of CTIP1 or CTIP2 in mammalian cells 
results in deacetylation of histones H3 and/or 
H4 associated with the promoter region, in a 
SIRT1-dependent mechanism. CTIP-mediated 
transcriptional repression, as well as deacetylation 
of histone H3/H4 in CTIP1-transfected cells, is 
partially reversed by nicotinamide, an inhibitor of 
class III histone deacetylases [53, 54].
In addition to modulating the levels of AR by 
direct deacetylation of this transcription factor, 
discussed above, ligand-dependent recruitment of 
SIRT1 into AR transcriptional repressor complexes 
on AR-responsive promoters results in the deacet-
ylation of histone H3 locally [17].
SIRT2 also plays a role in histone deacetylation, 
in particular at histone residue H4-K16. SIRT2 is 
predominantly localized to the cytoplasmic com-
partment, where it serves to deacetylate α-tubulin. 
During mitosis, however, SIRT2 shuttles to the 
nucleus and deacetylates histone H4-K16 to pro-
mote chromatin condensation [28].
SIRT3 can also deacetylate Histone H4-K16 
and repress transcription in a gene-speciﬁ  c manner. 
SIRT3 exists in two forms, a full-length protein 
and a processed polypeptide lacking 142 amino 
acids at the N-terminus. Both the full-length and 
processed forms of SIRT3 deacetylate H4-K16 in 
vivo and repress gene transcription [60].
Tumor suppressor gene (TSG) silencing is a 
hallmark of cancer. Epigenetic mechanisms of 
silencing of tumor suppressor genes in some cases 
involves dense hypermethylation of 5’ CpG islands 
and local hypoacetylation of Lys-9 and -14 on 
histone H3 (H3-K9 and H3-K14, respectively). 
Recently, SIRT1 has been shown to localize to the 
promoters of several aberrantly-silenced TSGs in 
which 5’ CpG islands are densely hypermethylated, 
but not to these same promoters in cell lines in 
which the promoters are not hypermethylated and 
the genes are expressed. Inhibition of SIRT1 in 
breast and colon cancer cells causes increases in 
H4-K16 and H3-K9 acetylation at endogenous 
promoters and re-expression of silenced TSGs, 
despite full retention of promoter DNA hypermeth-
ylation. SIRT1, therefore, comprises a new com-
ponent of epigenetic TSG silencing that may 
potentially link some of the epigenetic changes 
associated with aging with those found in cancers, 
and provides new directions for potential thera-
peutic targeting these important genes for re-
expression [61].
In addition to deacetylation of H3 and H4, the 
linker histone H1 may also serve as a target of 
SIRT1 in genome-wide transcriptional repression 
[62]. Histone H1 is acetylated in vivo at Lys-26 
and can be deacetylated by SIRT1. SIRT1 61
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physically interacts with histone H1, and this 
interaction recruits histone H1 to establish repres-
sive chromatin domains. Upon induction of SIRT1 
activity, there is a reduction in H4-K16 acetylation 
in euchromatic chromosomal regions. This effect 
is accompanied by an enrichment of histone H1 at 
speciﬁ  c promoters, the spreading of heterochro-
matin marks like tri-Me H3-K9 and mono-Me 
H4-K20 throughout the coding region, and a 
decrease in the levels of methylation of H3-K79. 
Thus, a proposed model for SIRT1-mediated het-
erochromatin formation includes deacetylation of 
histone tails, recruitment and deacetylation of 
histone H1, and spreading of H3-K79 hypometh-
ylation with resultant silencing.
Interactions of Sirtuins with methyl-
transferase/chromatin-remodeling 
complexes
In addition to changes in acetylation in the 
N-terminal domains of histone polypeptides, meth-
ylation modiﬁ  cation in histone tails also plays an 
important role in the transition between open and 
compacted chromatin states. SIRT1 has been 
shown to interact with a number of methyltrans-
ferase/chromatin-remodeling complexes, suggest-
ing a role of SIRT1 at this level of transcriptional 
regulation.
Methylation at K27 of histone H3 is a repressive 
‘‘mark,’’ catalyzed by the SET-domain containing 
Enhancer of Zeste protein-2, Ezh2, in Polycomb 
Repressive Complexes (PRCs). Ezh2 is a histone-
lysine methyltransferase with activity dependent 
upon its association with other components of the 
PRCs. Recently, SIRT1 has been found to form a 
complex with isoform 2 of the PRC component Eed 
[63]. The association of SIRT1 with PRCs produces 
the differential histone substrate speciﬁ  cities of 
distinct PRCs. Although full functional role of this 
association is not yet understood, Ezh2 and SIRT1 
both are highly expressed in prostate cancer and 
are associated with prostate cancer progression 
[64–67] (and our unpublished data). Our recent, 
unpublished data also shows that SIRT1 plays a 
role in the silencing of TSG transcription in prostate 
cancer. Collectively, these ﬁ  ndings suggest that 
SIRT1 may interact with, and cooperate with, EzH2 
complexes to silence TSG transcription and pro-
mote prostate cancer progression.
Cooperation of deacetylases with other enzymes 
or other co-repressor proteins to remodel chromatin is 
suggested by the altered recruitment of 
methyl-CpG-binding proteins to a methylated CpG 
island after treatment of tumor cells with HDAC 
inhibitors. Human cells lacking DNA methyltrans-
ferase 1 (Dnmt1), but not those lacking Dnmt3b, 
demonstrate a loss of DNA methylation and an 
increase in the acetylation levels of Lys-16 on 
histone H4 at the rRNA genes. SIRT1, which dem-
onstrates a preference for Lys-16 H4, interacts with 
Dnmt1, and SIRT1 recruitment to the rRNA genes 
is abrogated in Dnmt1-knockout cells [68]. The 
observed DNA methylation and chromatin changes 
at rRNA genes in Dnmt1-knockout cells are asso-
ciated with a structurally disorganized nucleolus, 
which is fragmented into small nuclear masses. 
These ﬁ  ndings suggest a role for SIRT1, in concert 
with Dnmt1, as an epigenetic caretaker for the 
maintenance of nucleolar structure [68].
H3-K79 hypomethylation is found in 
transcriptionally-repressed regions in mammal 
genomes. SIRT1 over-expression results in the 
reduction of methylated histone H3-K79 at pro-
moters and within coding regions. H3-K79 
methylation restricts the spreading of Sir2p in 
yeast, and thus, methylation of this residue may 
constitute a “boundary mark,” separating hetero-
chromatic from euchromatic regions. These and 
other ﬁ  ndings suggest that acetylation/deacety-
lation and methylation of chromatin can be 
coordinately regulated [62].
Most recently, SIRT1 has been found to directly 
interact with and deacetylate the histone methyl-
transferase SUV39H1 (suppressor of variegation 
3–9 homologue 1), increasing its activity. Loss of 
SIRT1 strongly affects SUV39H1-dependent gen-
eration of H3K9me3 and impairs localization of 
heterochromatin protein 1 [69].
Other Mechanisms of Transcriptional 
Control by Sirtuins
Several reports have shown that SIRT1 can sup-
press gene transcription by binding directly at gene 
promoters, but the molecular mechanism underly-
ing this activity are not clear. For example, SIRT1 
represses the uncoupling protein (UCP) gene 
UCP2 by binding directly to the UCP2 promoter. 
In beta cell lines in which SIRT1 levels are reduced 
by SiRNA, UCP2 levels are elevated and insulin 
secretion is blunted. This up-regulation of UCP2 
is associated with a failure of cells to increase ATP 
levels after glucose stimulation. Knock-down of 62
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UCP2 restores insulin secretion in cells with 
reduced SIRT1, indicating that the defect in 
glucose-stimulated insulin secretion is due to 
induction of UCP2 by SIRT1 depletion [70].
Over-expression of SIRT7 increases rRNA 
transcription, whereas its down-regulation 
decreases rRNA transcription. Interestingly, SIRT7 
expression is enriched in tissues with a high pro-
liferative potential, such as liver, spleen, and testis. 
Conversely, tissues with a low cellular turnover 
rate, such as skeletal and heart muscle and brain, 
express low levels of SIRT7. SIRT7 appears to 
drive ribosome biogenesis in dividing cells, and 
has been associated with thyroid and breast cancers 
(62, 63).
Conclusion, Perspectives 
and Unanswered Questions
Since the initial identiﬁ  cation of p53 in 2001 as the 
ﬁ  rst transcription factor substrate of SIRT1, mul-
tiple diverse transcription factors and co-activator/
co-repressor proteins have been identiﬁ  ed as targets 
of SIRT1, enabling direct control of transcription 
by the Sirtuin family members (Table 1). SIRT1 
also modulates chromatin structure, and hence can 
also affect gene regulation through indirect mech-
anisms. Yet, there are many important aspects of 
transcriptional regulation by Sirtuins which require 
further investigation and elucidation. For example, 
although it is clear that Sirtuin proteins function in 
a concerted way with methytransferase and chro-
matin-remodeling complexes, the molecular details 
underlying this speciﬁ  c mechanism of transcrip-
tional control are unknown.
In this review, we have discussed the molecular 
regulatory events targeted by Sirtuins in gene 
transcriptional regulation. However, Sirtuins is 
subject to multiple post-translational modiﬁ  ca-
tions, the molecular roles of which remain largely 
uncharacterized. Furthermore, as these post-
translational modiﬁ  cations are effected by various 
signaling pathways, this presents yet another level 
of control of Sirtuins on transcription that remains 
to be elucidated in detail. As examples, phos-
phorylation of HuR by Chk2 regulates SIRT1 
expression. Depending on its phosphorylation 
state, HuR can cause SIRT1 mRNA to either be 
stabilized or degraded [71, 72]. Over-expression 
of the protein phosphatase CDC14B results in 
dephosphorylation of SIRT2, with a subsequent 
decrease in the levels of SIRT2 protein [73]. 
Inhibition of PI3Kinase activity alters SIRT1 
sub-cellular localization [25] and SIRT1 protein 
levels (our unpublished data). Precisely how SIRT1 
is regulated by PI3Kinase or by other post-
translational modiﬁ  cation, with respect to com-
partmental localization or protein levels, and its 
ultimate effects on transcriptional activity, are 
unknown. Whether post-translational modiﬁ  ca-
tions of Sirtuins affect the acetylation status of 
promoter elements in a gene-speciﬁ  c manner also 
remains to be determined. Certainly, identiﬁ  cation 
of physiologically-relevant signaling pathways 
which induce the activation or the inactivation of 
Sirtuins, and their consequences on transcription, 
will be important to our understanding of this 
central transcriptional regulator.
Another perhaps surprising but major question 
which remains unanswered is whether SIRT1 is a 
tumor suppressor or, instead, an oncogene. While 
multiple lines of evidence suggest that Sirtuins 
protect against cancer development [16, 17, 74], 
several forms of cancer are characterized by ele-
vated levels of SIRT1 in the tumor cells, and these 
malignant cells may be dependent upon SIRT1 for 
their proliferation and survival (Sirtuin “addic-
tion”) [61, 67, 75–77]. For example, in prostate 
cancer, SIRT1 is required for androgen antagonist-
mediated transcriptional repression and growth 
suppression [17], and deacetylation of the AR by 
SIRT1 inactivates its ability to transform prostate 
cells [16]. Conversely, SIRT1 has been shown to 
be over-expressed in cancer cells and to promote 
cancer cell survival [75, 77]. Our unpublished data 
demonstrates that SIRT1 silences speciﬁ  c tumor 
suppressor genes in refractory prostate cancer cells, 
that SIRT1 is over-expressed both in the nucleus 
and cytoplasm of prostate cancer cells, and that 
this over-expression is associated with prostate 
cancer progression. These seemingly conﬂ  icting 
data suggest that SIRT1 may play dual roles in 
cancer progression, depending upon the physio-
logical conditions of the organism, or the stage of 
the cancer. For example, in the case of prostate 
cancer, we hypothesize that during the adult devel-
opment of prostate, as the expression level of 
SIRT1 decreases with aging, this promotes replica-
tive senescence and protects against tumorigenesis 
(although paradoxically also increasing the sensi-
tivity of this tissue to androgen stimulation). At 
this point, SIRT1 serves as a tumor suppressor. 
However, with the development of cancer, loss of 
tumor-suppressor genes such as HIC1 and p53, 63
Sirtuins in transcription regulation
Translational Oncogenomics 2008:3 
which regulate SIRT1 expression, may then lead 
to the over-expression of SIRT1. Through conse-
quent SIRT1-induced silencing of tumor suppres-
sor genes, SIRT1 then plays a role in cancer 
progression, promoting oncogenesis. Future work 
in this area, utilizing tissue—restricted transgenic 
or gene knock-out mouse models is need to fully 
understand such dichotomous roles for SIRT1 in 
cancer protection and progression.
Poised as they are, at the critical intersection of 
processes as diverse as aging, cancer susceptibility 
and metabolic regulation, a clearer mechanistic 
understanding of the central role that Sirtuins play 
at multiple levels in transcriptional control is of 
great importance.
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